Bristol-Myers Squibb Company
Triazolopyridine inhibitors of myeloperoxidase

Last updated:

Abstract:

The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. ##STR00001##

Status:
Grant
Type:

Utility

Filling date:

10 Mar 2017

Issue date:

13 Jul 2021